Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $10 | $15 | $23 | $15 |
| % Growth | -33.2% | -36.6% | 55.6% | – |
| Cost of Goods Sold | $2 | $3 | $0 | $0 |
| Gross Profit | $8 | $12 | $23 | $15 |
| % Margin | 77.3% | 80.1% | 100% | 100% |
| R&D Expenses | $108 | $112 | $100 | $76 |
| G&A Expenses | $28 | $29 | $23 | $21 |
| SG&A Expenses | $28 | $29 | $23 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$106 | -$102 | $0 | $0 |
| Operating Expenses | $31 | $39 | $123 | $97 |
| Operating Income | -$129 | -$136 | -$99 | -$82 |
| % Margin | -1,298.2% | -913.1% | -423.3% | -545.3% |
| Other Income/Exp. Net | -$36 | $41 | $13 | -$2 |
| Pre-Tax Income | -$165 | -$95 | -$87 | -$84 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$165 | -$95 | -$87 | -$84 |
| % Margin | -1,656.3% | -636.1% | -368.5% | -556.8% |
| EPS | -5.81 | -7.49 | -13.84 | -18.25 |
| % Growth | 22.4% | 45.9% | 24.2% | – |
| EPS Diluted | -5.81 | -7.49 | -13.84 | -18.25 |
| Weighted Avg Shares Out | 28 | 13 | 6 | 5 |
| Weighted Avg Shares Out Dil | 28 | 13 | 6 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $2 | $0 | $0 |
| Interest Expense | $5 | $4 | $4 | $2 |
| Depreciation & Amortization | $2 | $3 | $3 | $3 |
| EBITDA | -$157 | -$88 | -$80 | -$79 |
| % Margin | -1,582.1% | -588.4% | -339% | -524.8% |